文献速递临床免疫分子诊断

抗Ro52抗体在卵巢癌中高发且提示预后较好

Anti-Ro52 antibody is highly prevalent and a marker of better prognosis in patients with ovarian cancer.
PubMed 文献 · Clin Chim Acta · 2021-07-08

该研究在490例多种恶性肿瘤患者中检测抗Ro52抗体反应性,发现卵巢癌患者抗Ro52抗体阳性率显著高于其他6种恶性肿瘤,且阳性与更好的总生存期强相关;表位定位显示卵巢癌患者的Ro52表位谱与SLE和SjS不同,较少识别Ro52-1和Ro52-4片段。

要点

  • 卵巢癌患者抗Ro52抗体阳性率达30%,显著高于其他恶性肿瘤。
  • 卵巢癌中抗Ro52抗体阳性与更好的总生存期强相关。
  • 卵巢癌患者Ro52表位谱不同于SLE和SjS,较少识别Ro52-1和Ro52-4。

核心结论

  • 首次发现卵巢癌患者抗Ro52抗体频率意外地高,其存在提示更好的总生存期。
  • 卵巢癌患者抗Ro52抗体的表位谱不同于SLE和SjS,提示非SLE或SjS相关刺激诱导自身抗体产生。

研究设计与样本

  • 在490例多种恶性肿瘤患者的大型队列中检测抗Ro52抗体反应性。
  • 采用内部线免疫分析法,使用覆盖Ro52的5个重组Ro52多肽进行Ro52自身抗体表位定位。

主要发现

  • 抗Ro52抗体在卵巢癌患者中阳性率为30%,显著高于其他6种恶性肿瘤患者(中位8.1%,范围5.9-15.8%)。
  • 卵巢癌患者中抗Ro52抗体存在与更好的总生存期强相关。
  • 卵巢癌患者Ro52表位定位与SLE和SjS自身免疫风湿病患者不同,较少识别Ro52-1和Ro52-4片段。

关键数值与推荐

  • 卵巢癌患者抗Ro52抗体阳性率30%,其他6种恶性肿瘤中位阳性率8.1%(范围5.9-15.8%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Anti-Ro52 antibody (Ab) reactivity is highly prevalent in autoimmune rheumatic diseases (ARDs), mainly Sjögren's syndrome (SjS) and systemic lupus erythematosus (SLE), but also in other inflammatory disorders. Thorough assessment of the prevalence, clinical significance and epitope specificity of Ro52-autoAbs in cancerous diseases is still lacking. MATERIAL AND METHODS: Anti-Ro52 Ab reactivity was tested in a large cohort of 490 patients with various malignant diseases. Ro52-autoAb epitope mapping by an in house line immunoassay was carried out using 5 recombinant Ro52 polypeptides spanning Ro52. RESULTS: Anti-Ro52 abs were significantly more prevalent in patients with ovarian cancer (30%) compared to patients with 6 other malignant diseases (median 8.1%, range 5.9-15.8%). The presence of anti-Ro52 abs in patients with ovarian cancer was strongly associated with better overall survival. Ro52 epitope mapping of patients with ovarian cancer was dissimilar to that of SLE and SjS ARDs, less frequently recognizing Ro52-1 and Ro52-4 fragments compared to patients with SLE and SjS. CONCLUSION: We demonstrate for first time an unexpectedly high frequency of anti-Ro52 abs in patients with ovarian cancer, their presence indicating better overall survival. Their distinguishing epitope profile may suggest a non-SLE or SjS-related stimulus for autoAb production.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Bogdanos DP, Gkoutzourelas A, Papadopoulos V, et al. Anti-Ro52 antibody is highly prevalent and a marker of better prognosis in patients with ovarian cancer. Clin Chim Acta. 2021. PMID: 34245687. doi:10.1016/j.cca.2021.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。